Medicaid reimbursement and the uptake of adolescent vaccines.
BACKGROUND
In light of low adolescent vaccination rates, state-level policies that could improve vaccine coverage should be evaluated. Approximately 1/3 of adolescents are eligible, primarily through Medicaid enrollment, to receive vaccines from state-administered Vaccines for Children (VFC) programs. We investigated whether Medicaid reimbursement, the scope of implementation of VFC programs (i.e. limited or universal purchase), and/or presence of school-based vaccine mandates were associated with adolescent vaccination levels.


METHODS
We performed a cross-sectional analysis of state-level associations between these policies and 2009 National Immunization Survey-TEEN vaccination rates for tetanus-containing, meningococcal conjugate (MCV4), and among females only, human papillomavirus (HPV) vaccines.


RESULTS
Medicaid reimbursement was not associated with vaccine coverage rates after adjusting for presence of vaccine-related school mandates, type of VFC program, proportion of adolescents attending preventive care visits, and state-specific distribution of insurance coverage. Participation in a more expansive VFC program (universal or universal-select) was significantly associated with HPV vaccine coverage, but not tetanus-containing vaccine or MCV4, among states that had mandates for any vaccines.


CONCLUSIONS
Our results suggest that, contrary to what has been shown for childhood vaccines, raising Medicaid reimbursement rates may not improve adolescent vaccine utilization. Instead, other policy changes may be more effective, such as expansion of VFC programs into universal purchase programs, further implementation of school-based vaccine mandates and efforts to raise preventive care visits among adolescents.
Child Health Evaluation and Research Unit, University of Michigan, Department of Pediatrics, Ann Arbor, MI 48109-5456, USA.
Charitha
C
Gowda
Amanda F
AF
Dempsey
D000293:Adolescent; D003430:Cross-Sectional Studies; D005260:Female; D006291:Health Policy; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D007349:Insurance, Health, Reimbursement / Q000191:economics* / Q000331:legislation & jurisprudence; D008484:Medicaid / Q000191:economics* / Q000331:legislation & jurisprudence; D022401:Meningococcal Vaccines / Q000008:administration & dosage; D053918:Papillomavirus Vaccines / Q000008:administration & dosage; D013745:Tetanus Toxoid / Q000008:administration & dosage; D014481:United States; D014611:Vaccination / Q000706:statistics & numerical data*
D022401:Meningococcal Vaccines; D053918:Papillomavirus Vaccines; D013745:Tetanus Toxoid